EUVIMEDDécouvrir EUVIMED
Leserbrief

Reply to: Patient‐reported quality of life and acceptance of the extravascular implantable cardioverter‐defibrillator: Results from pivotal study

Alessandro Vicentini, Roberto Rordorf iD

Journal of Cardiovascular Electrophysiology · 2024

DOI: 10.1111/jce.16167 ↗

At a glance

Leserbrief in Journal of Cardiovascular Electrophysiology, 2024. Written by Alessandro Vicentini and 1 co-authors. Institution: Cardiac Intensive Care Unit, Arrhythmia and Electrophysiology and Experimental Cardiology, IRCCS Fondazione Policlinico S. Matteo, Pavia, Italy. Major MEDLINE topics: Defibrillators, Implantable. 9 references.

RésuméSubjectsRéférences bibliographiquesCiteRelated studies

Abstract (original language)

We read with interest the paper by Sears et al.,1 addressing the quality of life and acceptance of the extravascular implantable cardioverter-defibrillator (EV-ICD). The study presents results from EV-ICD patients and compares them with our previously published data in the Journal of Cardiovascular Electrophysiology on patients with subcutaneous implantable cardioverter-defibrillator (S-ICD) or transvenous implantable cardioverter-defibrillator (T-ICD).2 We find this work compelling as it provides essential data on a novel therapeutic solution, complementing our study that focused on the only therapeutic options available at the time of our analysis. We would like to add some more insights that we believe would be beneficial to the journal's readers in interpreting the results. A comparison of the methods employed in the two studies reveals some differences. Firstly, the assessment of patient acceptance occurred at different time points. We administered the Florida Patient Acceptance Survey (FPAS)3 at 12 months, while EV-ICD patients were interviewed at 6 months. Secondly, we evaluated device acceptance in consecutive patients receiving S-ICD in clinical practice, while the EV-ICD group was a subset of patients enrolled in the EV-ICD Pivotal Study.4 As acknowledged in Sears et al.'s work,1 this difference may introduce bias, given that the EV-ICD sample was based on the initial group of patients willing to accept a novel technology, potentially differing from those who declined or were ineligible for the study. The most significant distinction between the studies lies in the patient populations analyzed. We initially assessed device acceptance in 176 S-ICD patients and compared them with consecutive patients receiving T-ICD at our centers. To avoid biases favoring S-ICD therapy, we only compared the subgroup of 101 S-ICD patients with heart failure with reduced ejection fraction (HFrEF), best matching the T-ICD patients. In the study by Sears et al., the EV-ICD group was similar to our overall group of S-ICD patients in terms of some clinical characteristics (e.g., age, prevalence of cardiomyopathies) but differed in others, such as body mass index (BMI: 29 vs. 26 kg/m2). Sears et al. compared EV-ICD patients only with the S-ICD subgroup with HFrEF, making the two groups less comparable. This resulted in a higher average age of the S-ICD group (56 vs. 53 years of EV-ICD), more frequent ischemic/nonischemic cardiomyopathy (100% vs. 61%), lower ejection fraction (32% vs. 42%), and a lower BMI (27 vs. 29 kg/m2). Selecting older S-ICD patients may have influenced the FPAS scores obtained, as we observed lower FPAS values in older patients due to a significantly worse return to function (RTF) component.2 Another potential bias arises from including only HFrEF patients, as in our study, the median FPAS was 72 in HFrEF patients and 80 in non-HFrEF patients (RTF: 69 vs. 81). Moreover, the variable that, in our opinion, makes the groups less comparable is BMI. Sears et al. reported that stratifying EV-ICD patients by BMI < 25 kg/m2 or ≥25 kg/m2 resulted in significant differences in body image concerns (BIC) (27.3 vs. 11.5). If we consider only patients with BMI < 25 kg/m2 and compare EV-ICD and S-ICD (both HFrEF and non-HFrEF), we observe similar values (total FPAS Score: 78 vs. 80; RTF: 76 vs. 75; device-related distress: 26 vs. 20; positive appraisal: 88 vs. 88; BIC: 27 vs. 25). In the editorial accompanying our article,5 Dr. Sears highlighted that patient-reported outcomes allow a comprehensive examination of the patient experience, representing the “missing piece” to full technology evaluation after safety and efficacy have been demonstrated. He also emphasized the importance of long-term follow-up, since young patients are more likely to receive these devices, and pointed out that randomized,6, 7 observational8 trials, and meta-analyses9 have confirmed that S-ICD is at least as effective and safe as T-ICD for preventing sudden cardiac death, with observation periods longer than 4 years. Currently, EV-ICD has only demonstrated safety and effectiveness in a single study of 316 cases over 6 months.4 In conclusion, we believe that additional studies aimed at evaluating various outcomes, including patient acceptance, are essential to compare the two systems using similar methods and on similar populations. Roberto Rordorf received speaker fees from Abbott and Boston Scientific. The other author declares no conflict of interest.

Subjects

MeSH terms (MEDLINE)

Defibrillators, ImplantableHumansQuality of LifePatient Reported Outcome Measures

Authors and institutions

  • Cardiac Intensive Care Unit, Arrhythmia and Electrophysiology and Experimental Cardiology, IRCCS Fondazione Policlinico S. Matteo, Pavia, Italy.

ORCID profiles: Roberto Rordorf

Cite

APA

Vicentini, A., & Rordorf, R. (2024). Reply to: Patient‐reported quality of life and acceptance of the extravascular implantable cardioverter‐defibrillator: Results from pivotal study. Journal of Cardiovascular Electrophysiology. https://doi.org/10.1111/jce.16167

Vancouver

Vicentini A, Rordorf R. Reply to: Patient‐reported quality of life and acceptance of the extravascular implantable cardioverter‐defibrillator: Results from pivotal study. Journal of Cardiovascular Electrophysiology. 2024. doi:10.1111/jce.16167

BibTeX
@article{Vicentini2024,
  author = {Vicentini, Alessandro and Rordorf, Roberto},
  title = {Reply to: Patient‐reported quality of life and acceptance of the extravascular implantable cardioverter‐defibrillator: Results from pivotal study},
  journal = {Journal of Cardiovascular Electrophysiology},
  year = {2024},
  doi = {10.1111/jce.16167}
}
Start for free →